Most MS specialists recommend a brain MRI at least once a year for monitoring, though the right schedule depends heavily on where you are in the disease, what treatment you’re on, and how stable things have been. That “once a year” starting point is just that: a starting point. Newer evidence suggests some people can safely stretch the interval, while others need scans every three to six months. The details matter more than the general rule, and the science behind those details has shifted in the last few years.
The Baseline and Re-Baseline Scans
Before any monitoring schedule begins, you need a high-quality reference MRI. Current consensus guidelines recommend that diagnostic imaging cover both the brain and spinal cord and include specialized sequences that help identify features like the central vein sign and paramagnetic rim lesions, which assist with diagnosis when conventional imaging is ambiguous.1PubMed. 2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis This initial scan establishes what your disease “looks like” at a given moment so that future scans have something to compare against.
A separate re-baseline scan is generally recommended a few months after starting or switching a disease-modifying therapy. The logic is straightforward: new lesions that appeared before your treatment had time to work shouldn’t be counted as treatment failures. A re-baseline taken roughly three to six months into a new therapy gives your neurologist a clean reference point. Any new lesions that show up after that are more fairly attributable to breakthrough disease activity rather than the lag between starting medication and achieving full immune suppression.
Annual MRI for Most People, but the Interval Can Stretch
For someone with relapsing-remitting MS on a disease-modifying therapy, yearly brain MRI is the most commonly cited monitoring frequency. The goal is to catch new or enlarging lesions that you might not feel. A large study in the journal Brain found that people with clinically “silent” new lesions on MRI had roughly twice the risk of relapse over two years compared to those without such lesions, and a meaningfully higher rate of disability worsening.2PubMed. Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis In other words, the scan often tells you something your body hasn’t told you yet, and catching that early can prompt a therapy switch before you accumulate damage.
That said, annual scanning isn’t a one-size-fits-all rule. A recent analysis of patients on ocrelizumab found that the number of scans needed to detect one case of new disease activity increased over time, especially after the second year of treatment. The researchers suggested that for people with stable disease on this therapy, the interval between scans can be safely doubled from treatment year two onward, meaning a scan at re-baseline, year one, year two, then year four, then year eight, and so on.3PubMed Central. Value of Annual MRI Monitoring in Patients With Multiple Sclerosis Treated With Ocrelizumab: A Number Needed to Scan Analysis This “number needed to scan” approach reflects a practical reality: if someone has shown no new activity for several years on a highly effective therapy, scanning them every twelve months starts producing diminishing returns.
Whether your neurologist adopts this approach depends on several factors, including how aggressive your disease was before treatment, how long you’ve been stable, and your own comfort level with less frequent monitoring. The early years after diagnosis or after starting a new therapy are when scans matter most. Once stability is well established, there’s room for the schedule to relax.
Progressive MS Requires Its Own Strategy
People with progressive forms of MS present a different monitoring challenge. Relapses are less common, but slow-burning inflammation and neurodegeneration continue. A study in Brain Communications found that among patients initially classified as having non-active progressive MS, more than half developed detectable disease activity during follow-up. Among those who transitioned from non-active to active, about three-quarters were caught by MRI alone, with no accompanying relapse.4Brain Communications. MRI versus relapse: optimal activity monitoring for management of progressive multiple sclerosis
This finding makes a strong case for continuing regular MRI surveillance even in progressive MS, where many patients and clinicians might assume the scans are less useful because obvious relapses have tapered off. The disease can still be simmering in ways only imaging will reveal. How often to scan in progressive MS isn’t settled by any single guideline, but annual or biannual brain MRI is reasonable for most people, particularly those on treatments where detecting breakthrough inflammation might change the management plan.
When More Frequent Scanning Is Warranted
Certain situations push the monitoring frequency well above once a year. The clearest example involves natalizumab, a highly effective therapy that carries a risk of progressive multifocal leukoencephalopathy, a serious and sometimes fatal brain infection caused by the JC virus. Patients who are JC virus antibody-positive and have been on natalizumab for an extended period are at elevated risk, and catching PML early dramatically improves outcomes. Research has shown that the PML lesion is typically small when first detected on frequent surveillance scans, and patients who were monitored with regular MRI had better clinical outcomes.5PubMed. Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate For high-risk natalizumab patients, scanning every three to six months is standard practice at many MS centers.
Other situations that might trigger more frequent scanning include the first year on a new therapy (to confirm it’s working), a suspected relapse where clinical symptoms are ambiguous, or evidence of recent disease activity that prompts closer surveillance while a treatment change takes effect.
The Gadolinium Question
If you’ve had an MRI with contrast, you’ve received gadolinium, a substance injected intravenously that lights up areas of active inflammation. At diagnosis, gadolinium is quite valuable because enhancing lesions help confirm how recently inflammation occurred. But for routine follow-up scans, the picture has changed.
A review in Acta Médica Portuguesa concluded that it’s feasible and safe to exclude gadolinium from routine MS follow-up scans. The detection of enhancing lesions that don’t also appear as new or enlarged spots on standard T2-weighted images is rare, and the impact of finding such lesions on treatment decisions is questionable.6Acta Médica Portuguesa. Use of Gadolinium in Follow-Up MRI of Multiple Sclerosis Patients: Current Recommendations A separate review by European radiology and MS working groups reinforced this, noting that while gadolinium remains highly valuable at diagnostic workup, routine monitoring can rely on identifying new or enlarging lesions on unenhanced T2-weighted images without mandatory contrast.7PubMed. Use of gadolinium-based contrast agents in multiple sclerosis: a review by the ESMRMB-GREC and ESNR Multiple Sclerosis Working Group
This matters for people who are getting scanned repeatedly over years or decades. Although no clear clinical harm has been linked to retained gadolinium in the brain, health authorities in Europe and North America have recommended limiting its use to situations where it’s genuinely needed. If you’re getting a routine annual surveillance scan and your neurologist hasn’t specifically requested contrast, a non-contrast MRI is the current standard of care for monitoring. There are exceptions: if a relapse is suspected, if diagnostic uncertainty exists, or if PML surveillance is needed, gadolinium still adds meaningful information.
Despite these recommendations, real-world practice hasn’t fully caught up. A survey of MS imaging practices found that gadolinium was administered in about 87% of follow-up examinations, well above what current guidelines suggest is necessary.8PubMed Central. Walk Your Talk: Real-World Adherence to Guidelines on the Use of MRI in Multiple Sclerosis If your MRI orders routinely include contrast for surveillance, it’s worth discussing with your neurologist whether that’s specifically needed for your situation.
Does Spinal Cord Imaging Need to Be Routine?
Brain MRI is the workhorse of MS monitoring, but what about the spinal cord? Spinal cord lesions are important for diagnosis and contribute to disability, yet the evidence on whether routine spinal cord imaging adds much during follow-up is mixed.
A study of over 1,200 clinically stable MS patients found that new cervical spinal cord lesions occurred in fewer than 2% of people who had no simultaneous new brain lesions. Having new asymptomatic spinal cord lesions did not independently increase the risk of relapse or disability worsening over a median follow-up of about two years. The researchers concluded that brain MRI alone captures the vast majority of clinically silent disease activity, and spinal cord imaging may not be warranted for routine monitoring in most people.9PubMed. Limited utility of adding 3T cervical spinal cord MRI to monitor disease activity in multiple sclerosis
On the other hand, a review in Brain Communications painted a more nuanced picture, noting that one-third of patients in a retrospective study had new demyelinating lesions exclusively in the spinal cord, and including spinal cord imaging alongside brain MRI reduced the proportion of patients who appeared to have no evidence of disease activity by nearly 8%.10Brain Communications. Spinal cord evaluation in multiple sclerosis: clinical and radiological associations, present and future The practical takeaway is that spinal cord MRI during follow-up is most useful when someone has a history of spinal cord involvement, when new neurological symptoms suggest a cord lesion, or when the treatment team is using a strict “no evidence of disease activity” target. For the average stable patient getting routine surveillance, brain-only MRI is sufficient most of the time, but the conversation is worth having with your neurologist.
Pregnancy and Postpartum
Pregnancy introduces a unique monitoring timeline. Many women pause their disease-modifying therapy before or during pregnancy, and while MS relapses tend to decrease during the second and third trimesters, the postpartum period is a well-recognized danger zone for disease reactivation.
A study in Neurology: Neuroimmunology & Neuroinflammation found that almost one-third of postpartum surveillance MRIs showed new inflammatory lesions, even in women who were not suspected of having clinical relapses.11PubMed Central. Clinical and Radiologic Disease Activity in Pregnancy and Postpartum in MS The researchers recommended a baseline MRI before conception attempts, followed by a surveillance MRI in the first trimester postpartum. That early postpartum scan can prompt earlier resumption of therapy or a switch to a more effective treatment, potentially preventing damage that would otherwise go undetected until symptoms appeared. If you’re planning a pregnancy and have MS, getting a pre-conception reference scan and a postpartum follow-up onto the schedule early is a concrete step that’s well supported by the evidence.
Does Scanner Strength Affect How Often You Need Scans?
You might wonder whether a higher-powered MRI scanner gives better results and could change the monitoring calculus. Most clinical MRI is done at 1.5 Tesla (1.5T) or 3 Tesla (3T). A multicenter study found that 3T detected about 15% more T2 brain lesions than 1.5T, but this did not translate into a higher rate of MS diagnosis at any time point during the study.12PubMed Central. Three-Tesla MRI does not improve the diagnosis of multiple sclerosis: A multicenter study In practice, both field strengths are considered adequate for MS monitoring.
Where 3T does appear to have an edge is in correlating lesion burden with cognitive and physical outcomes. A study comparing the two found that lesion volumes measured at 3T correlated more strongly with disability scores and cognitive test performance than volumes measured at 1.5T.13PubMed Central. Brain MRI lesion load at 1.5T and 3T vs. clinical status in multiple sclerosis For clinical monitoring, the most important factor isn’t the field strength itself but consistency: getting scans on the same scanner, or at least the same field strength, over time so that comparisons between scans are reliable. Switching between 1.5T and 3T between visits can introduce measurement variability that makes it harder to judge whether a change is real or just a technical artifact.14PubMed Central. Quantifying brain volumes for Multiple Sclerosis patients follow-up in clinical practice – comparison of 1.5 and 3 Tesla magnetic resonance imaging
AI-Assisted Reading and What It Means for Monitoring
One of the more interesting recent developments is the use of artificial intelligence to help detect new lesions on follow-up scans. Comparing two MRIs taken a year apart and spotting a tiny new white spot among dozens or hundreds of existing lesions is one of the hardest tasks in neuroradiology. Even experienced readers miss subtle changes.
A study published in Scientific Reports compared a fully automated AI system with an expert-adjudicated workflow. The AI-only assessment flagged disease activity roughly twice as often as the expert-reviewed process, which means it was detecting more changes but also generating more false alarms. Agreement between the two approaches was high overall, but the AI was notably more sensitive, picking up more new lesions per scan. Negative agreement was strong at about 96%, meaning the AI and experts almost always agreed when there was nothing new to find.15Nature / Scientific Reports. Automated AI-based detection of MRI disease activity in multiple sclerosis: comparison with an expert-adjudicated AI-assisted workflow
This technology is still in the process of being integrated into routine clinical workflows, but it has the potential to improve the sensitivity of follow-up scans, especially in busy radiology departments where the time available per scan read is limited. For patients, the practical implication is that AI-assisted lesion detection may eventually make each scan more informative, potentially supporting longer intervals between scans with greater confidence that nothing is being missed.
The Cost and Access Side of MRI Scheduling
Guidelines are one thing; getting the scan done is another. MRI is expensive, and out-of-pocket costs affect how reliably people stick to their monitoring schedules. A study examining the relationship between financial liability and MRI follow-up in MS found a significant association between higher out-of-pocket costs and longer gaps between scans. People who owed more for their initial MRI took longer to come back for the next one.16Clinical Neuroimaging. Effects of financial toxicity and socioeconomic status on MRI follow‐up time in multiple sclerosis
This is worth acknowledging because the “ideal” monitoring frequency assumes equal access. If cost is a barrier for you, it’s worth raising this with your neurology team. Some centers have programs to help with imaging costs, and your neurologist can help prioritize which scans are most critical versus which can be safely delayed. A skipped scan isn’t the end of the world for a stable patient with years of clean imaging, but consistently avoiding monitoring altogether can leave disease activity undetected for long stretches.
Advanced MRI Markers on the Horizon
Standard MS monitoring counts lesions and checks whether they’re new or bigger. But researchers are increasingly interested in more sophisticated imaging markers that could give a deeper read on disease progression. Paramagnetic rim lesions, for instance, are lesions surrounded by a rim of iron-laden immune cells visible on susceptibility-weighted MRI. These lesions are thought to represent sites of chronic, smoldering inflammation. A study using 7T MRI identified rim lesions and cortical lesions as significant predictors of disability change over time, independent of traditional lesion counts.17Brain Communications. Cortical and phase rim lesions on 7 T MRI as markers of multiple sclerosis disease progression
The 2024 MAGNIMS-CMSC-NAIMS consensus recommendations already include susceptibility-sensitive sequences for the assessment of paramagnetic rim lesions in the diagnostic MRI protocol.1PubMed. 2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis As these advanced markers move from research into clinical practice, they could reshape how monitoring scans are interpreted. Instead of just asking “are there new lesions?” the question might become “are existing lesions smoldering?” That would add a new dimension to treatment decisions and might change not just how often scans are done but what the radiologist and neurologist are looking for when they read them.
Radiologically Isolated Syndrome
One unusual situation worth mentioning is radiologically isolated syndrome, where lesions that look like MS are found incidentally on an MRI done for some other reason, such as a headache or a head injury, in someone with no MS symptoms. Studies following these individuals have found that more than two-thirds developed new lesions over time, and nearly one-third eventually experienced a first clinical event consistent with MS.18SpringerLink / PubMed Central. The radiologically isolated syndrome: take action when the unexpected is uncovered? For people in this category, periodic MRI monitoring is essential to determine whether the disease is evolving, even though they feel perfectly fine. The exact schedule depends on features of the initial scan, but monitoring typically starts at six to twelve months and continues based on what subsequent scans show.